Literature DB >> 10770438

Gianotti-Crosti syndrome presenting as lichenoid dermatitis.

C M Stefanato1, L J Goldberg, W K Andersen, J Bhawan.   

Abstract

Papular acrodermatitis of childhood (Gianotti-Crosti syndrome) is an uncommon, self-limited disease characterized by an erythematous papular eruption symmetrically distributed on the face and limbs and mild lymphadenopathy, thought to be of viral origin. The histopathologic findings are nonspecific and include focal parakeratosis, mild spongiosis, superficial perivascular infiltrate, papillary dermal edema, and extravasated red blood cells. Interface changes with some basal vacuolization may be present, but are not a conspicuous feature. We present a 2 1/2-year-old boy with multiple papules and plaques on the face and extremities and cervical lymphadenopathy. Histopathologic analysis showed compact orthokeratosis, focal parakeratosis, hypergranulosis, psoriasiform epidermal hyperplasia, and a dense lichenoid lymphohistiocytic infiltrate with extensive exocytosis of mononuclear cells. Immunoperoxidase staining with CD 1 a revealed clusters of Langerhans cells in the epidermis and in the papillary dermis. In view of the clinical findings, a diagnosis of Gianotti-Crosti syndrome was made. Although there are a few reports describing a lichenoid pattern of infiltration in Gianotti-Crosti syndrome, this histologic pattern is not widely known. This case is presented to illustrate the fact that Gianotti-Crosti syndrome can present as lichenoid dermatitis, and, especially in children, should be added to the differential diagnoses of lichenoid infiltrates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10770438     DOI: 10.1097/00000372-200004000-00013

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  1 in total

1.  Simultaneous Development of Gianotti-Crosti Syndrome and Erythema Multiforme Following Second Dose of Measles-rubella Vaccine.

Authors:  Masahiro Oka
Journal:  Acta Derm Venereol       Date:  2021-04-26       Impact factor: 3.875

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.